Novo Holdings A/S bought $10.0M of AVLN
owner at Avalyn Pharma Inc.. 555,555 shares at an average of $18.00, traded May 1, 2026, filed May 5, 2026.
Score components
- +12Role10% owner
- +25Trade size$10.0M at market
- +3Relative to holdingsHoldings up 17%
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -1.6%, 3m +12.0%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001388325-26-000021, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 1, 2026 | CConversion Voting Common Stock | +3,327,734 | - | - | 3,327,734 | May 5, 2026 |
| May 1, 2026 | POpen-market purchase Voting Common Stock | +555,555 | $18.00 | $10.0M | 3,883,289 | May 5, 2026 |
| May 1, 2026 | CConversion Series A Preferred Stockderivative | -18,000,000 | $0.00 | $0 | 0 | May 5, 2026 |
| May 1, 2026 | CConversion Series B Preferred Stockderivative | -1,986,369 | $0.00 | $0 | 0 | May 5, 2026 |
| May 1, 2026 | CConversion Series C-1 Preferred Stockderivative | -25,899,284 | $0.00 | $0 | 0 | May 5, 2026 |
| May 1, 2026 | CConversion Series C-2 Preferred Stockderivative | -5,587,603 | $0.00 | $0 | 0 | May 5, 2026 |
| May 1, 2026 | CConversion Series D Preferred Stockderivative | -12,558,081 | $0.00 | $0 | 0 | May 5, 2026 |
Related signals
Other insiders at Avalyn Pharma Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 53Moderate | Avalyn Pharma Inc. | Sr One Capital Management, LLC owner | $10.0M 555,555 shares | +29% | |
| 58Moderate | Avalyn Pharma Inc. | Jill Carroll director | $5.0M 277,778 shares | +15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.